R&D and Producer of Interventional Medical Devices for Heart Disease

Following the launch of C-Wave, the first domestically produced shock wave system in China, in June 2023®After listing, HuiHe Healthcare recently launched a compatibleC-Wave of .018" Guidewire System®Intravascular Shockwave Catheter,Officially Approved by the National Medical Products Administration (NMPA) for Market Launch! Thus, HuiHe Healthcare's C-Wave®Becoming the first to simultaneously feature .014" and .018" guidewire systems, while also integrating peripheral and coronary intravascular lithotripsy systems.


C-Wave®As a breakthrough innovative technology, the peripheral shock wave system has changed the existing treatment strategy for calcified lesions. It generates shock waves with instantaneous energy up to 50 atm through intracatheter lithoplasty technology, promoting micro-cracks in calcified plaques, "softening" the plaques, restoring lumen compliance, maximizing lumen gain, and minimizing vascular injury, providing more treatment options for subsequent therapies. C-Wave®As the first domestically produced and self-developed shock wave system in China, it has been continuously receiving positive feedback from clinical applications since its market launch.The iterative upgrade of this product willMore aligned with the application needs at the clinical end, improving surgical efficiency, and ultimately ensuring patient benefits from the surgery.

Compatible with .018" guidewire, reducing 2 exchanges
For lesions that do not require pre-dilation, according to C-Wave®Balloon Catheter Diameter: Refer to the target vessel diameter 1.1:1 to directly select the appropriate size and length of C-Wave.®,Along .018"The guidewire is in place in one step, no guidewire exchange is required, and the next step of treatment can be performed directly.But for complex lesions that require pre-dilation, .018"• C-Wave® compared to .014"Guidewire Platform for OperatorsAt leastReduce two guidewire exchange operations, improve surgical efficiency, and minimize additional losses caused by system exchanges. The retained .014 system will continue to provide support for cases requiring combined debulking.
6Fr Sheath Compatibility with All Models
.018"•C-Wave® While increasing the inner diameter of the guidewire lumen, further optimize the balloon winding technology to maintain compatibility with .014."System Consistent Outer Diameter,All models of catheters are compatible with 6Fr and above sheaths.
Moving Forward, Smooth and Precise
135cm Effective Catheter Length
.018"• C-Wave®The balloon catheter has a longer effective length, with all models reaching up to 135cm.The selection of access routes will no longer be limited by catheter length, ensuring the choice of the most reasonable path.
Catheter tip outer diameter as fine as 0.7mm
C-Wave®The outer diameter of the balloon tip is only 0.7mm, and through a short tapered smooth transition, it can be delivered during the balloon insertion process.Reduce push resistance, assist in breakthrough, and ensure smooth positioning.。
One Continuous Stroke, Worry-Free Long Segments
10 electrodes, 300 pulses/bar
.018"• C-Wave® maintains the effective energy distribution of the original system. The long catheter above the knee has 10 evenly distributed electrodes, breaking through the electrode limit to achieve a total energy of 300 pulse waves for all models with a single catheter.Achieves 360° full-fan energy uniform coverage through an innovative electrode layout. The energy remains consistent from far to near, eliminating the need for precise electrode alignment during the procedure—ready to emit upon arrival for efficient calcium cracking.
Length: 40/60/80mm
Balloon catheters of different lengths are matched with different lesion lengths, and treatment methods are reasonably combined. The 80mm specification reduces the number of balloon overlaps.90% of patients only need one catheter to complete the lumen preparation.
Innovative at Heart, Committed to Clinical Excellence
C-Wave®Developed and manufactured by the ZhongHui team of HuiHe Healthcare, it has currently applied for 72 patents globally and in China, with 45 already authorized, including 11 invention patents.
HuiHe Healthcare has more than 120 R&D personnel, an 8,000-square-meter R&D and production site, over 260 patents in total, including 170 invention patents and more than 10 PCTs. Currently, it has the K-Clip.®Transcatheter Tricuspid Annuloplasty System, Vispearl®Radiopaque Drug-Eluting Embolic Microspheres, S-wanTMDual-control bend catheter sheath and other products.In the future, HuiHe Healthcare will continue to focus on the research, development, and intelligent manufacturing of innovative products in the fields of structural heart disease, coronary vascular intervention, peripheral vascular intervention, oncology vascular intervention, and smart intervention!
New Generation .018"System C-Wave®Shockwave Heating Up Trials
Welcome partners from all channels to contact HuiHe Healthcare:
| Region | Sales Director | Contact Information |
| Shanghai and Zhejiang | Ms. Guo | 15021081936 |
| Mr. Chen | 18092026036 | |
| Ms. Zhang | 18678781791 | |
If you have any questions, comments, suggestions, or cooperation needs regarding HuiHe Healthcare's products, please contact the company's inquiry email:question@hh-healthcare.com | ||


